Click on the name of drug to access data sheet
OCALIVA (OCA), Laboratory : INTERCEPT
Type of drug : FXR Agonist
Clinical trials advancement : Analysing Results Phase 3
The drug got the Breakthrough Therapy Status granted by the FDA and is eligible for Subpart H on intermediate results of Phase 3
Estimated Time to market in months : 10
ELAFIBRANOR (GFT505), Laboratory : GENFIT
Type of drug : dual PPAR alpha delta agonist
Clinical trials advancement : Ongoing Phase 3
The drug got the Fast Track Status granted by the FDA and is eligible for Subpart H on intermediate results of Phase 3
Estimated Time to market in months : 15
CENICRIVIROC (CENICRIVIROC), Laboratory : ALLERGAN
Type of drug : CCR2CCR5 Antagonist
Clinical trials advancement : Recruiting Phase 3
The drug got the Fast Track Status granted by the FDA and is eligible for Subpart H on intermediate results of Phase 3
Estimated Time to market in months : 37
RESMETIROM (MGL_3196), Laboratory : MADRIGAL
Type of drug : THR-β Agonist
Clinical trials advancement : Initiating Phase 3
and is eligible for Subpart H on intermediate results of Phase 3
Estimated Time to market in months : 42
BELAPECTIN (GR_MD_02), Laboratory : GALECTIN
Type of drug : Galectin Inhibitor
Clinical trials advancement : Initiating Phase 3
The drug got the Fast Track Status granted by the FDA
Estimated Time to market in months : 46
IMM124E (IMM124E), Laboratory : IMMURON
Type of drug : anti-LPS antibodies and adjuvants
Clinical trials advancement : Initiating Phase 3
The drug got the Breakthrough Therapy Status granted by the FDA
Estimated Time to market in months : 52
FIRSOCOSTAT (GS0976), Laboratory : GILEAD
Type of drug : ACC inhibitor
Clinical trials advancement : Initiating Phase 3
The drug got the Fast Track Status granted by the FDA
Estimated Time to market in months : 54
ARAMCHOL (ARAMCHOL), Laboratory : GALMED
Type of drug : FABACs
Clinical trials advancement : Analysing Results Phase 2b
The drug got the Fast Track Status granted by the FDA
Estimated Time to market in months : 53
CILOFEXOR (GS9674), Laboratory : GILEAD
Type of drug : FXR agonist
Clinical trials advancement : Analysing Results Phase 2b
Estimated Time to market in months : 78
MSDC_0602 (MSDC_0602), Laboratory : CIRIUS_THERAPEUTICS
Type of drug : mTOT modulating insulin sensitizer
Clinical trials advancement : Ongoing Phase 2b
Estimated Time to market in months : 88
TROPIFEXOR (LJN452), Laboratory : NOVARTIS
Type of drug : non-BA FXR agonist
Clinical trials advancement : Ongoing Phase 2b
Estimated Time to market in months : 90
NGM282 (NGM282), Laboratory : NGMBioPHARM
Type of drug : FGF19 hormon
Clinical trials advancement : Ongoing Phase 2b
Estimated Time to market in months : 88
SEMAGLUTIDE (SEMAGLUTIDE), Laboratory : NOVONORDISK
Type of drug : GLP_1analog
Clinical trials advancement : Ongoing Phase 2b
Estimated Time to market in months : 90
SELADELPAR (MBX_8025), Laboratory : CYMABAY_THERAPEUTICS
Type of drug : PPAR delta receptor agonist
Clinical trials advancement : Ongoing Phase 2b
Estimated Time to market in months : 98
LMB763 (LMB763), Laboratory : NOVARTIS
Type of drug : non-BA FXR agonist
Clinical trials advancement : Recruiting Phase 2b
Estimated Time to market in months : 94
LANIFIBRANOR (IVA337), Laboratory : INVENTIVA
Type of drug : tri PPAR α δ γ
Clinical trials advancement : Recruiting Phase 2b
Estimated Time to market in months : 100
SAROGLITAZAR (SAROGLITAZAR), Laboratory : ZYDUS
Type of drug : dual PPAR-α γ agonist
Clinical trials advancement : Initiating Phase 2b
Estimated Time to market in months : 103
BMS986036 (BMS986036), Laboratory : Bristol-MyersSquibb
Type of drug : PEG-FGF21
Clinical trials advancement : Initiating Phase 2b
Estimated Time to market in months : 104
EYP001 (EYP001), Laboratory : ENYOPHARMA
Type of drug : Non BA FXR agonist
Clinical trials advancement : Initiating Phase 2b
Estimated Time to market in months : 112
ISOSABUTATE (ISOSABUTATE), Laboratory : NORTHSEA_THERAPEUTICS
Type of drug : SEFA Structurally Engineered Fatty Acid
Clinical trials advancement : Initiating Phase 2b
Estimated Time to market in months : 112
GRI_0621 (GRI_0621), Laboratory : GRIPharma
Type of drug : NKT I Inhibitor
Clinical trials advancement : Analysing Results Phase 2a
Estimated Time to market in months : 112
BMS_986171 (pegbelfermin), Laboratory : Bristol-MyersSquibb
Type of drug : PEG-FGF21
Clinical trials advancement : Analysing Results Phase 2a
Estimated Time to market in months : 112
VK2809 (VK2809), Laboratory : VIKING
Type of drug : THR-? Agonist prodrug
Clinical trials advancement : Analysing Results Phase 2a
Estimated Time to market in months : 94
TIPELUKAST (TIPELUKAST), Laboratory : MEDICINOVA
Type of drug : (5-LOLT) inibitor
Clinical trials advancement : Analysing Results Phase 2a
The drug got the Fast Track Status granted by the FDA
Estimated Time to market in months : 90
NALMEFENE (JKB121), Laboratory : TaiwanJPharmaceuticals
Type of drug : Opioid receptor antagonists; Toll-like receptor 4 antagonists
Clinical trials advancement : Ongoing Phase 2a
Estimated Time to market in months : 114
LIK066 (LIK066), Laboratory : NOVARTIS
Type of drug : SGLT1-SGLT2 inhibitor
Clinical trials advancement : Ongoing Phase 2a
Estimated Time to market in months : 114
TESAMORELIN (EGRIFTA), Laboratory : Theratechnologies
Type of drug : growth hormone releasing hormone (GHRH) analogue
Clinical trials advancement : Ongoing Phase 2a
Estimated Time to market in months : 96
DF102 (AF102), Laboratory : AFIMMUNE
Type of drug : Undefined mechanism
Clinical trials advancement : Ongoing Phase 2a
The drug got the Fast Track Status granted by the FDA
Estimated Time to market in months : 91
NAMODENOSON (NAMODENOSON), Laboratory : CANFITE
Type of drug : A3AR Agonist
Clinical trials advancement : Ongoing Phase 2a
Estimated Time to market in months : 116
MT_3995 (MT-3995), Laboratory : MitsubishiTanabePharma
Type of drug : Aldosterone receptor antagonists
Clinical trials advancement : Ongoing Phase 2a
Estimated Time to market in months : 117
NITAZOXANIDE (NITAZOXANIDE), Laboratory : GENFIT
Type of drug : Stellate Cell activation
Clinical trials advancement : Ongoing Phase 2a
Estimated Time to market in months : 95
PF_05221304 (PF_05221304), Laboratory : PFIZER
Type of drug : Acetyl CoA-Carboxylase (ACC) Inhibitor
Clinical trials advancement : Ongoing Phase 2a
The drug got the Fast Track Status granted by the FDA
Estimated Time to market in months : 94
BI_1467335 (BI_1467335 or PXS-4728A), Laboratory : Boehringer_Ingelheim
Type of drug : VAP-1/AOC3 protein inhibitor
Clinical trials advancement : Ongoing Phase 2a
The drug got the Fast Track Status granted by the FDA
Estimated Time to market in months : 94
HTD1801 (HTD1801), Laboratory : HighTideTherapeutics
Type of drug : unknown mechanism of action
Clinical trials advancement : Recruiting Phase 2a
The drug got the Fast Track Status granted by the FDA
Estimated Time to market in months : 96
GEMCABENE (GEMCABENE), Laboratory : GEMPHIRE
Type of drug : enhance the clearance of VLDLs and may also inhibit ACC
Clinical trials advancement : Recruiting Phase 2a
Estimated Time to market in months : 121
FORALUMAB (FORALUMAB), Laboratory : TIZIANA
Type of drug : anti-CD3 monoclonal antibody (mAbs)
Clinical trials advancement : Initiating Phase 2a
Estimated Time to market in months : 122
PXL770 (PXL770), Laboratory : POXEL
Type of drug : (AMPK) activator
Clinical trials advancement : Initiating Phase 2a
Estimated Time to market in months : 123
SGM_1019 (SGM_1019), Laboratory : SecondGenome
Type of drug : P2X7 inhibitor
Clinical trials advancement : Initiating Phase 2a
Estimated Time to market in months : 122
CER_209 (CER_209), Laboratory : CERENIS
Type of drug : P2Y13 receptor agonist
Clinical trials advancement : Initiating Phase 2a
Estimated Time to market in months : 123
SAR425899 (SAR425899), Laboratory : SANOFI
Type of drug : GLP-1/GCGR agonist
Clinical trials advancement : Initiating Phase 2a
Estimated Time to market in months : 123
ELOBIXIBAT (A4250), Laboratory : AlbireoPharma
Type of drug : ileal bile acid transported (IBAT)
Clinical trials advancement : Initiating Phase 2a
Estimated Time to market in months : 123
SOTAGLIFLOZIN (LX4211), Laboratory : SANOFI
Type of drug : DUAL SGLT1 SGLT2 Inhibitor
Clinical trials advancement : Initiating Phase 2a
Estimated Time to market in months : 123
HEPASTEM (HEPASTEM), Laboratory : PROMETHERA
Type of drug : human liver derived mesenchymal stem
Clinical trials advancement : Initiating Phase 2a
Estimated Time to market in months : 123
BEZAFIBRATE (BEZAFIBRATE), Laboratory : INTERCEPT
Type of drug : tri PPAR alpha delta gamma
Clinical trials advancement : Initiating Phase 2a
Estimated Time to market in months : 129
TERN_101 (TERN_101), Laboratory : TERNS
Type of drug : FXR Agonist
Clinical trials advancement : Initiating Phase 2a
Estimated Time to market in months : 123
KBP_042 (KBP_042), Laboratory : NORDICBIOSCIENCE
Type of drug : (DACRA)
Clinical trials advancement : Analysing Results Phase 1
Estimated Time to market in months : 123
PF_06865571 (PF_06865571), Laboratory : PFIZER
Type of drug : Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor
Clinical trials advancement : Analysing Results Phase 1
Estimated Time to market in months : 123
DUR928 (DUR_928), Laboratory : DURECT
Type of drug : epigenetically-active endogenous small molecule
Clinical trials advancement : Analysing Results Phase 1
Estimated Time to market in months : 124
PF_06835919 (PF_06835919), Laboratory : PFIZER
Type of drug : Ketohexokinase (KHK) Inhibitor
Clinical trials advancement : Analysing Results Phase 1
Estimated Time to market in months : 124
NGM313 (MK-3655), Laboratory : Merck/NGMBio
Type of drug : β-Klotho/FGFR1c receptor
Clinical trials advancement : Analysing Results Phase 1
Estimated Time to market in months : 124
BIO89_100 (BIO89_100), Laboratory : 89BIO
Type of drug : glycopegylated FGF21 analogue
Clinical trials advancement : Analysing Results Phase 1
Estimated Time to market in months : 117
LPCN_1144 (LPCN_1144), Laboratory : LIPOCINE
Type of drug : novel oral prodrug of testosterone containing testosterone undecanoate
Clinical trials advancement : Analysing Results Phase 1
Estimated Time to market in months : 127
NAMACIZUMAB (RYI-018 or JNJ-2463), Laboratory : BIRDROCKBIO
Type of drug : NAMA-CB1
Clinical trials advancement : Analysing Results Phase 1
Estimated Time to market in months : 127
ND_L02_s0201 (ND_L02_s0201), Laboratory : NITTODENKO
Type of drug : (SERPINH1) (Hsp47)
Clinical trials advancement : Ongoing Phase 1
Estimated Time to market in months : 128
RTU_1096 (RTU_1096), Laboratory : SUCAMPO
Type of drug : Vap-1 inhibitor
Clinical trials advancement : Ongoing Phase 1
Estimated Time to market in months : 128
PLX_065 (DRX_065), Laboratory : POXEL
Type of drug : stabilized, preferred enantiomer of pioglitazone
Clinical trials advancement : Ongoing Phase 1
Estimated Time to market in months : 60
IONIS_DGAT2Rx (IONIS_DGAT2Rx), Laboratory : IONISPHARMA
Type of drug : DGAT2Rx
Clinical trials advancement : Ongoing Phase 1
Estimated Time to market in months : 129
INT_767 (INT_767), Laboratory : INTERCEPT
Type of drug : farnesoid X receptor (FXR) and TGR5, a G-protein coupled bile acid receptor
Clinical trials advancement : Ongoing Phase 1
Estimated Time to market in months : 131
EDP_305 (EDP_305), Laboratory : ENANTA
Type of drug : FXR agonist
Clinical trials advancement : Recruiting Phase 1
The drug got the Fast Track Status granted by the FDA
Estimated Time to market in months : 107
CM_101 (CM_101), Laboratory : ChemomAb
Type of drug : anti CCL24 monoclonal antibody
Clinical trials advancement : Recruiting Phase 1
Estimated Time to market in months : 134
TERN_201 (TERN_201), Laboratory : TERNS
Type of drug : SSAO Inhibitor
Clinical trials advancement : Recruiting Phase 1
Estimated Time to market in months : 134
HM15211 (HM15211), Laboratory : HanmiPharmaceutical
Type of drug : long-acting GLP-1, GIP and glucagon triple agonist
Clinical trials advancement : Recruiting Phase 1
Estimated Time to market in months : 134
CRV431 (CRV431), Laboratory : ContraVirPharmaceuticals
Type of drug : cyclophilin inhibitor
Clinical trials advancement : Recruiting Phase 1
Estimated Time to market in months : 122
NC_001 (NC_001), Laboratory : NAIAPHARMA
Type of drug : act on insulin resistance
Clinical trials advancement : Recruiting Phase 1
Estimated Time to market in months : 134
VK0214 (VK0214), Laboratory : VIKING
Type of drug : TRβ agonist
Clinical trials advancement : Preclinic
Estimated Time to market in months : 134
NV556 (NV556), Laboratory : NeuroVivePharmaceuticalAB
Type of drug : mild mitochondrial protonophores
Clinical trials advancement : Preclinic
Estimated Time to market in months : 134
AZD2693 (IONIS_AZ6_2.5_LRx), Laboratory : IONISPHARMA_ASTRAZENECA
Type of drug : NON DISCLOSED
Clinical trials advancement : Preclinic
Estimated Time to market in months : 134
NP160 (NP160), Laboratory : NashPharmaceuticals
Type of drug : ??
Clinical trials advancement : Preclinic
Estimated Time to market in months : 133
SP_1373 (VPD107), Laboratory : SPITFIRE_PHARMA
Type of drug : GLP1 Analog dual
Clinical trials advancement : Preclinic
Estimated Time to market in months : 135
RLBN1127 (RLBN1127), Laboratory : ACQUIST
Type of drug : Bifonctional Urates Inhibitors
Clinical trials advancement : Preclinic
Estimated Time to market in months : 136
NP135 (NP135), Laboratory : NashPharmaceuticals
Type of drug : ??
Clinical trials advancement : Preclinic
Estimated Time to market in months : 134
GKT_137831 (GKT_137831), Laboratory : GENKYOTEC
Type of drug : NOX1&4 inhibitor
Clinical trials advancement : Preclinic
Estimated Time to market in months : 136
NVP022 (NVP022), Laboratory : NeuroVivePharmaceuticalAB
Type of drug : mild mitochondrial protonophores
Clinical trials advancement : Preclinic
Estimated Time to market in months : 136
CB4209-CB4211 (CB4209-CB4211), Laboratory : CohBar
Type of drug : MOTS-c peptide analog
Clinical trials advancement : Preclinic
Estimated Time to market in months : 136
VPR_423 (VPR_423), Laboratory : VisionaryPharmaceuticals
Type of drug : RORgammaT
Clinical trials advancement : Preclinic
Estimated Time to market in months : 136
RYI_018 (RYI_018), Laboratory : CREATIVEBIOLAB
Type of drug : (CB-1)
Clinical trials advancement : Preclinic
Estimated Time to market in months : 136
